Details

Autor(en) / Beteiligte

• Boeck, S.
• Hoehler, T.
• Seipelt, G.
• Mahlberg, R.
• Wein, A.
• Hochhaus, A.
• Boeck, H.-P.
• Schmid, B.
• Kettner, E.
• Stauch, M.
• Lordick, F.
• Ko, Y.
• Geissler, M.
• Schoppmeyer, K.
• Kojouharoff, G.
• Golf, A.
• Neugebauer, S.
• Heinemann, V.

Titel

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

Ist Teil von

• Annals of oncology, 2008-02, Vol.19 (2), p.340-347

Ort / Verlag

Oxford: Oxford University Press

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• Background: To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). Patients and methods: At total of 190 patients were randomly assigned to receive capecitabine 1000 mg/m2 twice daily on days 1–14 plus oxaliplatin 130 mg/m2 on day 1 (CapOx), capecitabine 825 mg/m2 twice daily on days 1–14 plus gemcitabine 1000 mg/m2 on days 1 and 8 (CapGem) or gemcitabine 1000 mg/m2 on days 1 and 8 plus oxaliplatin 130 mg/m2 on day 8 (mGemOx). Treatment cycles were repeated every three weeks. The primary end point was progression-free survival (PFS) rate at 3 months; secondary end points included objective response rate, carbohydrate antigen 19-9 response, clinical benefit response, overall survival and toxicity. Results: The PFS rate after 3 months was 51% in the CapOx arm, 64% in the CapGem arm and 60% in the mGemOx arm. Median PFS was estimated with 4.2 months, 5.7 months and 3.9 months, respectively (P = 0.67). Corresponding median survival times were: 8.1 months (CapOx), 9.0 months (CapGem) and 6.9 months (mGemOx) (P = 0.56). Grade 3/4 hematological toxicities were more frequent in the two Gem-containing arms; grade 3/4 non-hematological toxicity rates did not exceed 15% in any arm. Conclusion: CapOx, CapGem and mGemOx have similar clinical efficacy in advanced PC. Each regimen has a distinct but manageable tolerability profile.